活动性类风湿关节炎患者调整DMARD治疗的时机与影响
该研究基于注册队列分析类风湿关节炎中高疾病活动度患者调整DMARD治疗的时机。
要点
- 90天内未调整DMARD与达到低活动度或缓解时间更长相关。
- 高龄、低基线活动度、长病程和生物制剂使用与调整延迟相关。
核心结论
- 90天内调整DMARD与更短达到低疾病活动度或缓解时间相关,但许多持续中高活动度患者等待超过90天才调整。
研究设计与样本
- 基于匹兹堡大学类风湿关节炎比较效果研究注册队列的回顾性分析,纳入538例中高疾病活动度RA患者,随访943.5患者年。
主要发现
- 所有受试者调整DMARD的中位时间为154天(IQR 1-706),达到低疾病活动度或缓解的中位时间为301天(IQR 140-706)。
- 高龄(SHR 0.61,P=0.02)、较低基线疾病活动度(SHR 0.72,P<0.01)、较长RA病程(SHR 0.98,P<0.01)和生物制剂使用(SHR 0.71,P<0.01)与调整时间更长显著相关。
- 非裔美国人种族(HR 0.63,P=0.01)、较高基线疾病活动度(HR 0.75,P<0.01)和90天内未调整DMARD(HR 0.76,P=0.01)与达到低疾病活动度或缓解时间更长相关。
临床怎么用
- 对持续中高疾病活动度的RA患者,应关注90天内调整DMARD的及时性,以促进更快达到治疗目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Guidelines recommend that rheumatoid arthritis (RA) patients with moderate-to-high disease activity (MHDAS) adjust disease-modifying antirheumatic drug (DMARD) therapy at least every 3 months until reaching low disease activity or remission (LDAS). We examined how quickly RA patients with MHDAS adjust DMARD therapy in clinical practice, and whether those who adjust DMARDs within 90 days in response to MHDAS reach LDAS sooner. METHODS: We identified RA patients with MHDAS in the University of Pittsburgh Rheumatoid Arthritis Comparative Effectiveness Research registry, and conducted a competing risks regression on time to DMARD therapy adjustment and a Cox regression on time to LDAS. RESULTS: We identified 538 eligible subjects with 943.5 patient-years of followup. Sixty percent of patients with persistent MHDAS adjusted DMARDs within 90 days. Among all subjects, median times to DMARD adjustment and LDAS were 154 (interquartile range [IQR] 1-706) days and 301 (IQR 140-706) days, respectively. Being elderly (subdistribution hazard ratio [SHR] 0.61, P = 0.02), lower baseline disease activity (SHR 0.72, P < 0.01), longer duration of RA (SHR 0.98, P < 0.01), and biologic use (SHR 0.71, P < 0.01) were significantly associated with longer times to therapy adjustment. African American race (hazard ratio [HR] 0.63, P = 0.01), higher baseline disease activity (HR 0.75, P < 0.01), and not adjusting DMARD therapy within 90 days (HR 0.76, P = 0.01) were associated with longer times to LDAS. CONCLUSION: Adjusting DMARDs within 90 days was associated with shorter times to LDAS, but many patients with persistent MHDAS waited >90 days to adjust DMARDs. Interventions are needed to address the timeliness of DMARD adjustments for RA patients with MHDAS.
引用
- Shaw Y, Chang CH, Levesque MC, et al. Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease. Arthritis Care Res (Hoboken). 2018. PMID: 28941147. doi:10.1002/acr.23418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。